A new study shows that a fermented product made from soybeans called ImmuBalanceInflammation of the respiratory tractsuppressed in asthma. Bronchial asthma causes symptoms such as wheezing and coughing due to a chronic respiratory disease. However, there is no basic treatment for it, giving rise to the desire for new methods of prevention and treatment. Now the researchers have found that in a mouse model treated with a fermented soy product, white blood cells associated with asthma were significantly reduced. These are known as eosinophils.
Could a fermented product made from soybeans provide asthma therapy?
In addition to a decrease in inflammation and mucus around the bronchi, the research team also observed a suppression of proteins that trigger eosinophilic inflammation. Imbalances in the gut microbiome may reportedly be involved in the immune system and allergic diseases. According to the study authors, fermented fiber, such as that found in soy, could have positive effects on allergic asthma. In the study, scientists examined the effects of such an imbalance on asthma by feeding diet enriched with ImmuBalance to mouse models of asthma. In the treated group, the number of eosinophils was significantly reduced. In addition, such a product made from soybeans was able to prevent inflammation around the bronchi and mucus production in the bronchial epithelium.
The researchers also measured the expression of Th2 cytokines and immunoglobulin serum IgE, which induce eosinophilic inflammation. Given the results compared to mice fed a normal diet, they found it to be significantly suppressed. Histological analysis of the lungs showed that ImmuBalance inhibited inflammatory cell infiltration and mucus production of the airways. In clinical practice, steroid inhalants are the basis of asthma treatments, but their side effects are well known. This is what the senior professor explainsthis study, Tomoya Kawaguchi. In addition, the new findings suggest that the consumption of fermented soybean products should be recommended as a complementary, low-side-effect management strategy for asthma.
